NAFLD Guidelines 2012

Given the pervasiveness of Non-alcoholic Fatty Liver Disease (NAFLD), updated practice guidelines are worth a look (Hepatology 2012; 55: 2005-23, also in Gastroenterology 2012; 142: 1592-1609)).  While the review includes updated information on incidence, prevalence, risk groups, natural history, the focus remains on specific graded recommendations.

These AGA/AASLD/ACG guidelines do not recommend screening adults due to uncertainties surrounding diagnostic tests and treatment.  This includes high risk populations such as diabetics and bariatric patients.  In addition, unlike recent obesity guidelines from the AAP (Pediatrics 2007; 120: S164-192), these guidelines do not recommend screening children for NAFLD.

Specific management recommendations:

  • Exclude competing etiologies in patients with suspected NAFLD: iron studies, autoantibodies, Wilson’s, viral hepatitis, celiac serology, muscle disease
  • Consider liver biopsy in higher risk patients: metabolic syndrome patients, patients with higher NAFLD Fibrosis score, or before treatment
  • Serum/plasma CK18 is promising biomarker.  Not recommended for routine practice at this time.

Treatment Recommendations:

  • Weight loss (3-5%) helps steatosis and greater losses (up to 10%) may be needed to improve necroinflammation.
  • Metformin –not recommended for liver disease in NASH/NAFLD.
  • Pioglitazone can be used to treat steatohepatitis; however, “long-term safety and efficacy of pioglitazone in patients with NASH is not established.”
  • Vitamin E at 800 units/day improves liver histology in biopsy-proven NASH.  Not recommended without biopsy-confirmed NASH, in diabetic patients, or patients with cirrhosis.  Concern with Vitamin E in adults has been an association with increased all-cause mortality in some studies (but not in others).
  • Avoid alcohol in patients with NAFLD

Website to download PDF version:

http://www.gastro.org/journals-publications/news/societies-develop-new-nafld-clinical-practice-guideline

Another opinion on which patients to biopsy:

http://www.gastro.org/journals-publications/aga-perspectives/june-july-2012/should-we-routinely-do-liver-biopsy-in-nafld-patients

Related posts:

A liver disease tsunami

13 thoughts on “NAFLD Guidelines 2012

  1. Pingback: Can NALFD be improved with bile acid sequestration? | gutsandgrowth

  2. Pingback: Six year outcomes with bariatric surgery | gutsandgrowth

  3. Pingback: Does NAFLD cause hepatocellular cancer? | gutsandgrowth

  4. Pingback: Could Cysteamine help NAFLD? | gutsandgrowth

  5. Pingback: Checklists for Crisis and Daily Care | gutsandgrowth

  6. Pingback: Pediatric NAFLD histology score | gutsandgrowth

  7. Pingback: Gut microbiome and endogenous alcohol | gutsandgrowth

  8. Pingback: Most Popular Posts | gutsandgrowth

  9. Pingback: In NASH, is ALT Wrongly Used as a Marker of Liver Injury? | gutsandgrowth

  10. Pingback: Fatty Liver at Birth | gutsandgrowth

  11. Pingback: When Will MRI Obviate the Need for a Liver Biopsy in Pediatric NAFLD? | gutsandgrowth

  12. Pingback: Concise Review: Fatty Liver in Pediatrics | gutsandgrowth

  13. Pingback: Most Popular Posts 2011-2018 | gutsandgrowth

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.